CLSI M57

Principles and Procedures for the Development of Epidemiological Cutoff Values for Antifungal Susceptibility Testing, 1st Edition

This guideline includes the criteria for developing and using epidemiological cutoff values for guiding clinical decisions when testing fungal species and antifungal agent combinations for which there are no breakpoints.

Supplemental tables for M57 are published in CLSI document M57S.

This reaffirmed document has been reviewed and confirmed as suitable to remain published without revision to content, as of February 2022. The document’s next scheduled review is generally five years after the reaffirmation date.

More Details

Member price:

List Price:

Add to Cart

Details

Chairholder: Barbara D. Alexander, MD, MHS

Date of Publication: April 30, 2016

Order Code PDF: CLSI M57Ed1E
ISBN Number: 1-56238-933-5

Order Code Print: CLSI M57Ed1
ISBN Number: 1-56238-932-7

Edition: First

Pages: 28

CLSI M57 Additional Details

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.

CLSI M57 Abstract

Clinical and Laboratory Standards Institute guideline M57—Principles and Procedures for the Development of Epidemiological Cutoff Values for Antifungal Susceptibility Testing presents criteria for determining epidemiological cutoff values (ECVs) for yeasts and filamentous fungi. Data collection, ECV development, and indications for their use are discussed. This guideline provides an analysis of the criteria that determine whether an isolate has a wild-type or non-wild-type minimal inhibitory concentration/minimal effective concentration value and discusses how ECVs can be used for fungal species and antifungal agent combinations for which there are no breakpoints.